Targeting intracellular protein turnover by inhibiting the ubiquitin–proteasome pathway as a
strategy for cancer therapy is a new addition to our chemotherapeutic armamentarium, and …

Proteasome inhibition has been shown to be an effective strategy for the treatment of
multiple myeloma, as demonstrated by the clinical activity of the first-in-class agent …

The multicatalytic proteinase complex, or proteasome, is responsible for the majority of
regulated eukaryotic protein turnover through the ubiquitin–proteasome pathway …

The ubiquitin–proteasome pathway is a principle intracellular mechanism for controlled
protein degradation and has recently emerged as an attractive target for anticancer …

The ubiquitin-proteasome pathway plays a central role in the targeted destruction of cellular
proteins, including cell cycle regulatory proteins. Because these pathways are critical for the …

Multiple myeloma remains incurable despite available therapies, and novel therapies that
target both tumor cell and bone marrow microenvironment are urgently needed. Preclinical …

Abstract Bortezomib (formerly PS-341) has been the first proteasome inhibitor to enter
clinical trials in cancer patients. Based on results of preclinical studies showing that this …

ABSTRACT Introduction: Proteasome inhibitors (PIs) are therapeutic backbones of multiple
myeloma treatment, with PI-based therapies being standards of care throughout the …

Proteasome inhibition has emerged as an important therapeutic strategy in multiple
myeloma (MM). Since the publication of the first phase 1 trials of bortezomib 10 years ago …

Abstract The coordinated regulation of cellular protein synthesis and degradation is
essential for normal cellular functioning. The ubiquitin proteasome system mediates the …